Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Alterations in Muscle Tone lll

Alterations in Muscle Tone lll

Rigidity and myotonia are distinct abnormalities of muscle tone that affect resistance and relaxation during movement. Although both involve altered muscle contraction, they arise from different neurological and muscular mechanisms.CharacteristicsRigidity is characterized by uniform resistance to passive movement across the entire range, independent of speed, affecting flexors and extensors equally. It may appear as lead-pipe rigidity (smooth, constant resistance) or cogwheel rigidity...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sex-related differences in postoperative complications after pelvic exenteration and their relationship with surgical invasiveness in a multicenter study.

Surgery today·2026

Same author

Impact of Prior Systemic Chemotherapy on Response to <i>ROS1</i> Tyrosine Kinase Inhibitors in <i>ROS1</i>-Rearranged Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.

JCO precision oncology·2026

Same author

Magnesium-Rich Mineral Water Improves Stool Consistency and Bowel Habits in Healthy Subjects: A Randomized Controlled Trial.

Neurogastroenterology and motility·2026

Same author

The novel antifungal agent NPD2560 perturbs the Rho1-centered signaling network to induce a cell wall integrity response.

Microbiology spectrum·2026

Same author

Identification and structural characterization of soluble dectin-1 with β-glucan-binding activity in THP-1 cell culture supernatant.

Immunobiology·2026

Same author

Clinical Efficacy of HER2-targeted Monotherapy in ERBB2-mutant Non-Small-Cell Lung Cancer: A Systematic Review and Single-arm Meta-Analysis.

Clinical lung cancer·2026

Search research articles

Related Experiment Video

Updated: May 12, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Rotigotine and parkinsonism-hyperpyrexia syndrome.

Shohei Watanabe¹, Ayano Hasuike¹, Hosho Morishita¹

¹Department of Neurology, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya City, Hyogo, Japan.

Clinical Parkinsonism & Related Disorders

|May 11, 2026

Summary

Parkinsonism-hyperpyrexia syndrome (PHS) is a severe condition often caused by medication changes in Parkinson's disease (PD). Rotigotine, a transdermal treatment, may help reduce PHS incidence, emphasizing medication adherence.

Keywords:

Parkinsonism-Hyperpyrexiasyndrome Parkinson’sdisease Rotigotine

More Related Videos

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Related Experiment Videos

Last Updated: May 12, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Area of Science:

Neurology
Pharmacology

Background:

Parkinsonism-hyperpyrexia syndrome (PHS) is a critical complication of Parkinson's disease (PD), frequently triggered by alterations in antiparkinsonian medications.
Rotigotine, a continuous-delivery transdermal dopamine agonist, offers an alternative administration route, especially when oral intake is challenging.

Purpose of the Study:

To investigate the association between rotigotine use and the development of PHS in hospitalized PD patients.
To identify clinical factors and precipitating events associated with PHS.

Main Methods:

Retrospective review of 147 emergency hospitalizations for PD.
Comparison of clinical characteristics, medication use, and precipitating factors between PHS and non-PHS groups.
Multivariable logistic regression analysis to assess predictors of PHS, including rotigotine administration.

Main Results:

The PHS group exhibited shorter disease duration and lower medication doses compared to the non-PHS group.
Poor medication compliance was the primary precipitating factor for PHS.
Rotigotine administration showed a trend towards suppressing PHS development (OR, 0.353; p=0.0569).

Conclusions:

While not statistically significant, rotigotine use may be associated with a reduced incidence of PHS.
Maintaining consistent medication adherence is crucial for PHS prevention.
Rotigotine presents a potential therapeutic option for managing PHS risk in PD patients.